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Abstract The combination of cytotoxic treatment with
strategies for immune activation represents an attractive
strategy for tumour therapy. Following reduction of high
tumour burden by eVective cytotoxic agents, two major
immune-stimulating approaches are being pursued. First,
innate immunity can be activated by monoclonal antibodies
triggering antibody-dependent cellular cytotoxicity. Sec-
ond, tumour-speciWc T cell responses can be generated by
immunization of patients with peptides derived from
tumour antigens and infused in soluble form or loaded onto
dendritic cells. The choice of cytotoxic agents for such
combinatory regimens is crucial since most substances such
as  Xudarabine are considered immunosuppressive while
others such as cyclophosphamide can have immunostimu-
latory activity. We tested in this study whether Xudarabine
and/or cyclophosphamide, which represent a very eVective
treatment regimen for chronic lymphocytic leukaemia,
would interfere with a therapeutic strategy of T cell activa-
tion. Analysis of peripheral blood samples from patients
prior and during Xudarabine/cyclophosphamide therapy
revealed rapid and sustained reduction of tumour cells but
also of CD4+ and CD8+ T cells. This correlated with a sig-
niWcant cytotoxic activity of Xudarabine/cyclophosphamide
on T cells in vitro. Unexpectedly, T cells surviving Xudara-
bine/cyclophosphamide treatment in vitro had a more
mature phenotype, while Xudarabine-treated T cells were
signiWcantly more responsive to mitogenic stimulation than
their untreated counterparts and showed a shift towards TH1
cytokine secretion. In conclusion, Xudarabine/cyclophos-
phamide therapy though inducing signiWcant and relevant
T cell depletion seems to generate a micromilieu suitable
for subsequent T cell activation.
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Introduction
In general, the success or failure of cancer immunotherapy
depends on whether eYcient stimulation of T cells and sub-
sequent establishment of an activated, tumour-speciWc
memory T cell pool is accomplished or not. While our
knowledge of the biology of tumour cells, antigen-present-
ing cells and their complex interactions with autologous T
cells increases, the challenges regarding clinical eYcacy of
immunotherapy remain to be resolved [1–6]. Among them
are the rather low frequency of tumour antigen-speciWc T
cells, their limited life span and their loss of cytolytic activ-
ity in vaccination studies [7]. It can also be expected that
the eYciency of T cell activation following vaccination is
generally reduced in patients with intrinsic T cell deWciencies.
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In chronic lymphocytic leukaemia (CLL), changes within
the T cell compartment comprise abnormal increase in
absolute CD4+ and CD8+ T cell numbers with abnormal
phenotype, such as increase in death receptor expression
[8], loss of costimulatory molecules necessary for stimula-
tion of antigen-presenting cells [9], abnormal cytokine/
receptor proWle [10], impaired formation of the immune
synapse [11] as well as accumulation of regulatory T cells
(Treg) [12, 13]. All these alterations might contribute to the
decreased responsiveness of T cells to antigenic stimulation
and to the hypogammaglobulinaemia observed in CLL
patients, making them highly susceptible to severe opportu-
nistic infections [14]. In addition, it might allow unhindered
expansion of the tumour clone in phases of disease progres-
sion or tumour relapse following therapy.
A combination of two agents, the nucleoside analogue
Xudarabine, and cyclophosphamide, a DNA-alkylating
agent, has been shown to be a highly eVective treatment for
CLL patients [15–17]. EYcacy can even be improved by
combining  Xudarabine/cyclophosphamide with additional
therapeutics like mitoxantron [18] or monoclonal antibod-
ies like rituximab [19–21]. It has already been shown that
cyclophosphamide, beside being cytoreductive, is able to
enhance lymphocyte reconstitution and immune responses
(for review [3,  22]), whereas Xudarabine is routinely
administered in the setting of allogeneic stem cell trans-
plantation and leads to prolonged immunosuppression [23].
The aim of our study was to characterize activation status,
subset distribution and functions of the T cell compartment




The study was conducted according to the Declaration of
Helsinki. After obtaining informed patient consent,
untreated CLL patients seen at the Department of Haema-
tology and Oncology, University Hospital Salzburg,
Austria between January 2005 and April 2010 were
included in this study. Peripheral blood mononuclear cells
(PBMCs) were collected in heparinized or EDTA-coated
tubes during routine examinations. CLL was deWned by
clinical criteria as well as by cellular morphology and the
coexpression of CD19, CD5, and CD23 in lymphocytes
simultaneously displaying restriction of light-chain rear-
rangement. Staging was performed according to modiWed
Rai classiWcation [24]. Characteristics of the patients
studied are presented in Table 1. For those experiments
where not all patients were included, the patient samples
were unselected.
PuriWcation of PBMC and cell culture
Peripheral blood mononuclear cells were separated by den-
sity centrifugation. Fresh blood samples were diluted 1:1
with RPMI 1640 (PAA Laboratories, Pasching, Austria)
and layered over Biocoll separating solution (Biochrom
AG, Berlin, Germany). The opaque layer on top of the Bio-
coll-containing PBMCs was collected, washed once with
phosphate-buVered saline (PBS) and resuspended in
complete medium [RPMI 1640 medium containing 2 mM
L-glutamine, 100 U/ml penicillin/streptomycin and 10%
fetal calf serum (FCS)]. PBMCs were then incubated at
37°C and 5% CO2 for 24 h in medium alone or in presence
of 1 g/ml Xudarabine (Sigma-Aldrich, MO, USA), 1 g/ml
mafosfamide (IIT GmbH, Bielefeld, Germany), or a combi-
nation of both. PBMCs were then washed and cultured for
up to 6 days in complete medium.
Flow cytometry analysis
For characterization of the T cell pool, fresh blood samples
or puriWed PBMCs were incubated for 15 min with a mix-
ture of Xuorochrome-labelled murine anti-human antibodies
directed to the following antigens: CD19 (R-phycoerythrin,
RPE), CD25 [Xuorescein isothiocyanate (FITC)] (all from BD
Biosciences, CA, USA), CD3 (phycoerythrin-cyanin 5, PC5),
Table 1 Patient characteristics
B-CLL B cell chronic lymphocytic leukaemia, Ig immunoglobulin, VH
variable heavy chain, nda no data available
Parameters No. of 
patients (%)











Low (0) 23 (42)
Intermediate (I/II) 27 (49)
High (III/IV) 5 (9)
Molecular risk parameters
Unmutated Ig VH 15 (29) (nda: 4)
Unfavourable genetic 
aberration(s) (del17p, 11q)
2 (4) (nda: 1)
CD38 + B-CLL (¸30%) 15 (29) (nda: 3)Cancer Immunol Immunother (2011) 60:75–85 77
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CD4 [(energy-coupled dye (ECD)], CD4 (phycoerythrin-
cyanin 7, PC7), CD8 (PC7), CD19 (PC7), CD38 (PE),
CD45RA (FITC), CD45RA (ECD), CD62L (PE), CD127
(PE) (all from Beckman Coulter, CA, USA), CD4 (cyanin 5,
Cy5), CD8 (FITC), CD8 (PC5) (all from DAKO, Glostrup,
Denmark). Viability was assessed by staining cells with
Annexin-V (FITC) (Alexis, Lausen, Switzerland) and 7-AAD
(Beckman Coulter). Subsequently, samples were washed with
PBS and analyzed immediately using the FC500 Xow cytome-
ter and the CXP1.0 software (Beckman Coulter).
For characterization of murine T cells, tail vein blood
was stained with Xuorochrome-labelled rat anti-mouse anti-
bodies directed to the following antigens: CD3 (FITC),
CD25 (PE), CD44 (cyanin 5.5), CCR4 (PC7), CXCR3
(Allophycocyanin; APC), CD4 (PaciWc Blue) (all from
BioLegend Europe, Uithoorn, the Netherlands) and CD8
(APC-H7) (BD Biosciences) for 15 min. Erythrocytes were
lysed using BD FACS Lysing solution (BD Biosciences).
Cells were then resuspended in PBS and analysed immedi-
ately using the Gallios Xow cytometer (Beckman Coulter).
Allogeneic dendritic cell preparation and mixed 
lymphocyte reaction
Peripheral blood mononuclear cells were puriWed by den-
sity centrifugation from buVy coats from healthy donors
retrieved from the local blood bank. Monocytes were
enriched by CD14 MicroBead-positive selection (Miltenyi,
Bergisch Gladbach, Germany) and cultivated in complete
medium in the presence of recombinant human interleukin
4 (rhIL-4,500 U/ml) and granulocyte macrophage colony-
stimulating factor (rhGM-CSF, 1,000 U/ml) (both from
CellGenix, Freiburg, Germany) for 6 days. Fresh rhIL-4
and rhGM-CSF was added on day 3. On day 6, purity of
diVerentiated dendritic cells was assessed by light micros-
copy and by Xow cytometry (CD14-Cy5, CD11c-PE,
CD83-FITC; Beckman Coulter). Cultures containing >90%
dendritic cells, displaying high expression of CD11c and
low expression of CD14 and CD83, were irradiated with
30 Gy and stored at ¡80°C until used.
Mixed lymphocyte reaction (MLR) was performed using
CLL PBMCs as responders and allogeneic dendritic cells
from six diVerent buVy coats as stimulators. In brief,
PBMCs from CLL patients were incubated for 24 h with
Xudarabine (1 g/ml) or medium alone. The cells were then
washed with PBS. Irradiated allogeneic dendritic cells were
thawed and viability was assessed by trypan blue inclusion.
CLL PBMCs and allogeneic dendritic cells were incubated
with 5 M 5(6)-carboxyXuorescein diacetate N-succinim-
idyl ester (CFSE, Sigma, MO, USA) at a concentration of
106 cells/ml in PBS for 5 min. CFSE incorporation was
stopped by adding complete medium and the cells were
washed once with complete medium. PBMCs from CLL
patients were seeded into 24-well Xat-bottom cell culture
plates (Corning, MA, USA) at a concentration of 2.5 £ 106
cells/ml/well. Irradiated CFSE-stained allogeneic dendritic
cells were added at a stimulator/responder ratio of 1:10 and
the coculture left untreated for 6 days. Using Xow cytome-
try the extent of proliferation was determined at the end of
the coculture period by assessing the fraction of cells which
had lost incorporated CFSE upon cell division and there-
fore displayed reduced CFSE Xuorescence intensity. In
some experiments, instead of allogeneic dendritic cells
polystyrene beads coated with a mixture of monoclonal
antibodies against CD3 and CD28 (Dynabeads® Human
CD3/CD28 T Cell Expander, Invitrogen, CA, USA) were
added to the 6-day PBMC culture in a PBMC/bead ratio of
250:1.
Cytokine release measurement by cytometric bead array
Peripheral blood mononuclear cells from CLL patients
were incubated for 24 h with Xudarabine (1 g/ml),
mafosfamide (the active form of cyclophosphamide 1 g/ml)
or a combination of both. The cells were then washed,
5 £ 106 PBMC were incubated either with medium alone
or stimulated with phorbol 12-myristate 13-acetate (PMA
1 ng/ml) and ionomycin (0.5 g/ml) (Sigma) for 6 days.
After the stimulation period, the culture supernatants were
collected and either immediately analyzed for presence of
cytokines or stored at ¡20°C for later analysis.
For evaluation of TH1 and TH2 cytokine production after
stimulation, we performed cytokine bead assays (CBAs)
according to the manufacturer’s recommendations (CBA
Human TH1/TH2 Cytokine Kit II; BD Biosciences).
Murine tcl1tg tumour transplantation model
A tcl1a transgenic (tcl1tg) mouse, which has the coding
region of human tcl1a placed under the control of a B cell-
speciWc IgVH-promoter and IgH-E enhancer was previ-
ously published as a mouse model for CLL. It develops
clonal CD5-positive B cell leukaemia manifested by
peripheral blood lymphocytosis and splenomegaly at a
median of 11 months [25–27]. These mice were back-
crossed onto pure C57BL/6 background to allow transfer of
primary tcl1tg tumour cells into immune competent (not
irradiated) syngeneic wild type C57BL/6 recipient mice. In
the transplanted mice, the time to disease onset is shortened
from 1 year to about 3 months, which vastly facilitates
analysis (Hofbauer JP, Egle A, unpublished [26]). Tumour
transplanted mice were treated with Xudarabine (intraperi-
toneal injections of 35 mg/kg/day of Xudarabine on 5 con-
secutive days) at the onset of disease (tumour load in
peripheral blood >30%). Mice were bled from the tail vein
at the indicated time points and T cell subsets were78 Cancer Immunol Immunother (2011) 60:75–85
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analysed. CD4+ and CD8+ memory cells were deWned by
low expression of CD25 and high expression of CD44. TH1
and TH2 cells were deWned by expression of the chemokine
receptors CXCR3 (TH1) and CCR4 (TH2).
Statistical analysis
All statistical analyses were performed using PASW Statis-
tics 17 (SPSS Inc. IL, USA) or Graph Pad Prism 5. Box-
plots show median (horizontal line in box), diVerence
between 25th and 75th percentile (length of box) and data
range (whiskers) unless stated otherwise. Outliers are
marked by circles. Values in the results section are in gen-
eral mean § standard deviation and p value (paired or
unpaired student’s t test). Graphics were created using
PASW Statistics 17 and Graph Pad Prism 5.
Results
Characterization of T cells after cytotoxic treatment
Peripheral blood mononuclear cells from previously
untreated CLL patients were isolated as described in
“Materials and methods”. For all in vitro experiments, we
used mafosfamide, the active form of cyclophosphamide,
since cyclophosphamide requires in vivo processing in the
liver. Cells were incubated in medium containing clinically
achieved concentrations of Xudarabine (Flu 1 g/ml),
mafosfamide (Maf 1 g/ml), or a combination of both
agents (FluMaf) [28]. After 24 h, cells were washed,
counted and cultivated for an additional period of 6 days.
Viability of CD4+ and CD8+ T cells and of CD19+ CLL
cells was determined on day 0 and day 6 by the Annexin V
binding assay (Table 2). While there was no signiWcant
reduction in viability detectable immediately after the 24-h
incubation with any of the single agents, the combined
FluMaf treatment signiWcantly reduced viability of tumour
cells and T cells when compared with medium control. Six
days post-treatment PBMCs showed signiWcantly reduced
viability in the CD4+, CD8+ T cell as well as in the CD19+
CLL cell compartment. We found no signiWcant correlation
of any of the investigated clinical risk parameters (Table 1)
with in vitro sensitivity of T cells to Xudarabine or mafosfa-
mide. Additionally, we calculated the ratio between CLL
cells and T cells before and 6 days after cytotoxic treat-
ment. We found a signiWcant increase in the CLL/T cell
ratio (Table 2) indicating a higher sensitivity of T cells to
cell death induced by Xudarabine and mafosfamide when
compared with CLL cells.
At the end of the 6-day culture period, T cells surviving
cytotoxic treatment were characterized with respect to
expression of the activation marker CD38, the relative dis-
tribution of naïve and memory T cells and the relative pro-
portion of Tregs within the T cell pool. The diVerence in
the numbers of the patient samples in Fig. 1 is based on the
strong reduction in cell numbers following cytotoxic treat-
ment in some cases that did not allow analysis. However,
all statistical analyses were calculated from paired samples.
We found a signiWcant reduction in the percentage of
CD38-expressing CD4+ T cells after treatment with
mafosfamide (26.6% § 12.8, p = .001) and FluMaf (22.2% §
20.3,  p = .048) when compared with untreated PBMCs
(38.3% § 20.4), while Xudarabine treatment had no eVect
on CD38 expression (35.6% § 24.4, p = .063) (Fig. 1a). In
the CD8+ T cell pool, such a reduction of relative numbers
of CD38+ T cells after treatment with mafosfamide or
FluMaf was also observed, yet to a lower extent probably
due to the generally lower CD38 expression on CD8+ T
cells (Fig. 1b; control 16.6% § 9.7; Flu 20.2% § 12.2,
p = .461; Maf 12.5% § 5.0, p = .031; FluMaf 3.6% § 3.1,
p = .112). When we compared the eVect of cytotoxic
treatment on absolute cell numbers, we found that CD38+
T cells were more sensitive to mafosfamide-induced
Table 2 Viability (%) and CLL/T cell ratio after 24 h cytotoxic treatment (Day 0) or subsequent 6 day culture in medium (Day 6)
P values reXect treatment compared to untreated medium control. SigniWcant diVerences are highlighted in bold (n =1 6 )
CD4+ T cells CD8+ T cells CLL cells CLL/T cell ratio
Day 0
Medium 91.2% § 1.8 87.8% § 2.8 68.9% § 5.0 20.7 § 4.2
Flu 89.6% § 1.9; p = .204 80.1% § 3.5; p = .135 65.2% § 5.9; p = .421 24.7 § 25.5; p = .155
Maf 91.9% § 1.7; p = .462 85.2% § 3.8; p = .284 68.5% § 6.7; p = .591 19.1 § 4.5; p = .435
FluMaf 88.2% § 2.0; p = .024 73.3% § 3.6; p < .001 45.4% § 6.6; p = .022 22.4 § 7.4; p = .432
Day 6
Medium 86.3% § 2.6 80.1% § 4.2 61.0% § 6.8 15.9 § 2.9
Flu 40.3% § 5.6; p < .001 26.6% § 5.7; p < .001 35.1% § 6.6; p = .001 43.9 § 9.9; p = .004
Maf 63.4% § 6.1; p < .001 50.9% § 6.6; p < .001 47.6% § 9.8; p = .015 23.2 § 5.7; p = .027
FluMaf 15.8% § 4.7; p < .001 6.4% § 2.7; p < .001 5.7% § 7.2; p < .001 65.6 § 16.4; p =. 0 0 1Cancer Immunol Immunother (2011) 60:75–85 79
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apoptosis than T cells lacking CD38 expression (not
shown). None of the clinical risk parameters depicted in
Table 1 correlated with altered CD38 expression on T cells
after cytotoxic treatment.
Tregs were deWned by high CD25 (IL-2R) and low
CD127 (IL-7R) expression levels within the CD4+ T cell
compartment. We found no signiWcant changes in the per-
centage of Tregs after treatment with any of the cytotoxic
agents alone or in combination (data not shown).
The expression proWle of the leucocyte homing receptor
L-selectin (CD62L) and CD45RA was used to distin-
guish between naïve (CD45RA+, CD62L+) and memory
(CD45RA¡) T cells (Fig. 1c, d). When compared to
untreated controls, Xudarabine- or mafosfamide-treated CD4+
T cells showed an elevated memory subset fraction (63.3% §
16.4 vs. 79.3% § 13.0, p < .001, or 73.1% § 15.8, p < .001,
respectively) that further increased following combined
treatment with the two agents (82.4% § 14.0,  p = .016).
Correspondingly, the percentage of naïve cells was
decreased. In the CD8+ T cell compartment, a shift towards
a memory phenotype could also be observed after cytotoxic
treatment (control 45.6% § 17.1; Flu 66.4% § 23.2, p < .001;
Maf 53.8% § 20.0,  p < .001; FluMaf 71.5% § 35.9,
p = .021).
Additionally, we evaluated the eVect of Xudarabine and
mafosfamide on T cells from healthy donors. The eVects
observed in CLL T cells were recapitulated in the healthy
T lymphocytes suggesting that these alterations are not
disease-speciWc (Suppl. Fig. 2a–d).
Functionality of in vitro Xudarabine-treated T cells: 
proliferation
To evaluate the ability of CLL T cells to proliferate follow-
ing cytotoxic treatment, we performed MLR. PBMCs from
16 untreated CLL patients were incubated for 24 h with
Xudarabine or medium alone. The cells were then washed
and co-cultured with allogeneic dendritic cells (DC) as
stimulators and after 6 days T cell proliferation rates were
measured by the CFSE dilution assay.
Upon stimulation with DC, the proliferating fraction of
Xudarabine-treated CD4+ and CD8+ T cells was signiW-
cantly higher than that of untreated T cells (43.4% § 5.0
vs. 25.7% § 5.1,  p < .001 and 40.9% § 6.7 vs. 23.1% §
6.0, p < .001, respectively) (Fig. 2a). To exclude the possi-
bility that increased proliferation was just a phenomenon of
increased stimulator:responder ratios due to the massive
cytoreduction by Xudarabine treatment, we correlated the
proliferation rates after 6 days with the extent of cytoreduc-
tion by Xudarabine. We could not observe any correlation
between cell reduction by Xudarabine treatment and prolif-
eration induction by DC (not shown, Pearson correlation:
Fig. 1 PBMCs from 27 untreat-
ed CLL patients were incubated 
for 24 h with complete medium 
alone, Xudarabine (1 g/ml), 
mafosfamide (1 g/ml) or both. 
The cells were then washed and 
cultured for subsequent 6 days in 
complete medium. On day 6, the 
fraction of CD38-expressing 
CD4+ (a)o r  C D 8 + (b)T  c e l l s  
was determined. T cell subsets 
were deWned as stated in the 
Results section and the fraction 
of memory CD4+ (c)a n d  C D 8 + 
(d) T cells was determined. 
Values signiWcantly diVerent 
from untreated controls are 
indicated by asterisks (*p <. 0 5 ;  
**p < .01; ***p < .001)80 Cancer Immunol Immunother (2011) 60:75–85
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0.216,  p = .389), ruling out a bias generated by variable
stimulator:responder ratios.
We next assessed the phenotype of the T cells expanding
in response to DC stimulation and therefore characterized
expression levels of CD38, CD62L and CD45RA on CD4+
and CD8+ T cells on day 6 of the MLR. CD38-expressing T
cells in general showed a higher proliferative activity than
T cells not expressing CD38 (Fig. 2b). When PBMCs had
been treated with Xudarabine, increased proliferation was
detected both in the CD4+CD38+ (26.5% § 10.1 vs.
46.2% § 10.0, p = .024) and in the CD4+CD38¡ T cell pool
(7.3% § 1.9 vs. 16.0% § 3.6,  p = .031), whereas the
increase in proliferation after Xudarabine treatment was sig-
niWcant in the CD8+CD38+ population (21.4% § 9.5 vs.
49.2% § 12.8, p = .011) and borderline signiWcant in the
CD8+CD38¡ T cell pool (1.3% § 0.3 vs. 4.7% § 1.5,
p = .054). We also determined whether there was a diVer-
ence in the capacity of naïve and memory T cells to prolif-
erate upon allogeneic stimulus after Xudarabine treatment.
We observed a signiWcantly higher proportion of proliferat-
ing T cells in the memory compartment as compared to
naïve T cells. Interestingly, naïve T cells showed no diVer-
ence in proliferation after Xudarabine treatment, whereas
both CD4+ and CD8+ memory T cells, when pre-treated
with  Xudarabine, showed higher proliferation than the
respective untreated controls (Fig. 2c; CD4+: 16.0% § 5.2
vs. 34.0% § 9.9,  p = .030; CD8+: 8.3% § 3.1 vs.
29.7% § 8.3, p = .009). In order to conWrm these results in
a setting that is independent of allogeneic antigen recogni-
tion, we performed proliferation assays using beads cou-
pled with CD3 and CD28 antibodies instead of
allogeneic DC. The CD4+ and CD8+ T cell proliferation
rate upon CD3/CD28 bead stimulation was signiWcantly
higher when the cells were pretreated with Xudarabine for
24 h (Fig. 2d, e; CD4+: 56.7% § 29.1 vs. 74.5% § 17.8,
p = .021; CD8+: 63.1% § 27.7 vs. 84.9% § 9.4, p = .005).
Additionally, absolute CD4+ T cells numbers after CD3/
CD28 bead stimulation were signiWcantly increased in the
Xudarabine-pretreated samples (p = .004), thus conWrming
and underlining the positive inXuence of Xudarabine on
T cell proliferation in an antigen-independent setting
(Fig. 2f). Fludarabine-induced increase in T cell prolifera-
tion after CD3/CD28 beads was recapitulated in healthy
T lymphocytes (Suppl. Fig. 2e, f).
Functionality of in vitro Xudarabine-treated T cells: 
cytokine secretion
TH1-type cytokines such as interferon gamma (IFN), inter-
leukin 2 (IL-2) and tumour necrosis factor alpha (TNF)
are considered key cytokines for T cell-mediated tumour
control, while TH2 cytokines, as IL-10, IL-4 and IL-6,
Fig. 2 a PBMCs from CLL patients (n = 16) were incubated for 24 h
with medium alone, or Xudarabine (1 g/ml). The cells were then
washed, stained with CFSE, and cultured for 6 days in the presence of
allogeneic DC at a ratio of 10:1. On day 6, the fraction of CFSE-diluted
T cells was assessed. The fraction of proliferating T cells in CD38-pos-
itive or negative T cell population (b) and in naïve or memory T cell
compartment (c) was measured (n =8 ) .  d PBMCs from CLL patients
(n = 16) were incubated for 24 h with medium alone, or Xudarabine
(1 g/ml). The cells were then washed, stained with CFSE, and cul-
tured for 6 days in the presence of beads coated with anti-CD3/anti-
CD28 antibodies at a PBMC/bead ratio of 250:1. On day 6, the fraction
of CFSE-diluted CD4+ (d) and CD8+ (e) T cells and the total CD4+ T
cell number (f) were assessed. SigniWcance is indicated by asterisks
(*p <. 0 5 ,  * * p < .01, ***p < .001) (white bars CD4+, grey bars CD8+
T cells)Cancer Immunol Immunother (2011) 60:75–85 81
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counteract diVerentiation of T cells to a TH1 subtype. We
therefore investigated the ability of Xudarabine- or
mafosfamide-treated T cells to produce TH1 or TH2 cyto-
kines upon stimulation with PMA/ionomycin.
We incubated PBMCs from untreated CLL patients with
Xudarabine (1 g/ml), mafosfamide (1 g/ml) or DMSO
(medium control) for 24 h. The cells were then washed and
were left untreated or stimulated for additional 6 days with
PMA (1 ng/ml) and ionomycin (0.5 g/ml). We collected
the culture supernatants and evaluated the concentration of
secreted cytokines by CBA.
As depicted in Fig. 3, we found that after 6 days of stim-
ulation with PMA/ionomycin, the supernatant of PBMCs
pre-treated with Xudarabine showed signiWcantly elevated
levels of the TH1 cytokines IFN ( p = .025) and IL-2
(p = .024). Mafosfamide did not signiWcantly alter the lev-
els of the two TH1 cytokines IFN ( p = .065) and IL-2
(p = .658). Furthermore, the TH2 cytokine IL-10 was sig-
niWcantly decreased in Xudarabine- (p = .016) but not in
mafosfamide- (p = .219) treated samples (Fig. 3). While
TNF levels remained nearly unaVected when compared to
untreated controls, IL-4 and IL-6 levels were either below
the detection limit of the CBA or, in the samples where
detection was possible, not signiWcantly altered by either
Xudarabine or mafosfamide treatment (data not shown). To
ascertain that the elevated TH1 cytokine levels originate
from T cells and not from the CLL cells, we performed
intracellular IFN staining of PBMCs after 24 h Xudarabine
treatment followed by 4 h PMA/ionomycin stimulation. We
did not detect intracellular IFN in CD19+ CD5+ CLL cells,
but IFN-positive cells within the CD19¡ CD5+ T cell pop-
ulation (Suppl. Fig. 1).
Characterization of CLL T cells after in vivo Xudarabine/
cyclophosphamide (FC) treatment
Since we observed changes in the T cell compartment after
in vitro treatment of CLL PBMCs with Xudarabine or
mafosfamide with respect to activation status, diVerentia-
tion, proliferation and cytokine secretion, we Wnally tested
whether treatment in vivo would yield similar results. We
therefore analyzed samples from chemonaïve CLL patients
who started a modiWed FC therapy protocol at our clinical
department. This protocol includes administration of Xudar-
abine (25 mg/m2/day i.v.) and cyclophosphamide (250 mg/
m2/day i.v.) over 4 days. We used samples drawn before
therapy (d0) and on day 1, 2 and 3 of the Wrst cycle for
expression and functional studies.
For functional analysis of T cell proliferation we col-
lected blood samples from FC-treated patients before treat-
ment, puriWed the lymphocytes and incubated them in vitro
for 24 h with or without 1 g/ml Xudarabine. In addition,
PBMCs from samples drawn after 1 or 3 days of in vivo FC
treatment were isolated. Cells were washed, stained with
CFSE and co-cultured for subsequent 6 days with DC at a
ratio 10:1. For each sample, the percentage of proliferating
T cells was measured on day 6 of the co-culture period
(Fig. 4a). When compared with untreated control cells, in
vitro incubation with Xudarabine increased the percentage
of proliferating CD4+ (15.9% § 5.3 vs. 24.2% § 8.2, p =
.049) and CD8+ (21.2% § 4.0 vs. 58.6% § 3.8, p = .001) T
cells. While there was no increase in T cell proliferation
after 24 h in vivo FC treatment, we detected increased frac-
tions of proliferating T cells after 3 days in vivo FC treat-
ment (CD4+ 15.9% § 5.3 vs. 33.1% § 8.7, p = .010; CD8+
21.2% § 4.0 vs. 75.7% § 8.4, p = .003).
We also compared expression of CD38 on CLL T cells
on day 0 and day 3 of the therapy and observed a slight
increase in CD4+CD38+ (54.3% § 2.8 vs. 58.3% § 3.8,
p = .387) and CD8+CD38+ T cells (51.1% § 4.2 vs.
59.4 § 4.9, p = .210) (Fig. 4b), that was not signiWcant. The
fraction of Tregs within the CD4+ T cells remained stable
over the Wrst 3 days of therapy (not shown). We Wnally
evaluated any changes in T cell subset distribution between
day 0 and day 3 of the FC treatment. The memory fraction
remained stable or even slightly decreased during this
Fig. 3 PBMCs from seven untreated CLL patients were incubated
with medium alone (co), Xudarabine (Flu 1 g/ml) or mafosfamide
(Maf 1 g/ml) for 24 h. The cells were then washed and incubated for
further 6 days in presence of PMA (1 ng/ml) and ionomycin (0.5 g/
ml) at a concentration of 2.5 £ 106 cells/ml. Culture supernatants were
collected and the concentration of cytokines (ng/ml) was measured by
cytokine bead assay (CBA). Values signiWcantly diVerent from untreated
controls are indicated by asterisks (*p < .05)82 Cancer Immunol Immunother (2011) 60:75–85
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period in the CD4+ (Fig. 4c, 74.3% § 4.4 vs. 60.9% § 7.9,
p = .150) and in the CD8+ (Fig. 4d, 45.3% § 4.5 vs.
31.6% § 4.9, p = .049) T cell compartment.
Characterization of T cells after in vivo Xudarabine 
treatment of tcl1 transgenic tumour transplanted mice
Since treatment of our patient cohort included administration
of rituximab [29] on day 4 of therapy, possible long-term
alterations in the T cell compartment following Xudarabine/
cyclophosphamide treatment in vivo could not be assessed in
these patients. Therefore, we used tcl1tg mice as a CLL
mouse model to address this question. We transplanted pri-
mary tcl1tg tumour cells into syngeneic wildtype mice. At
the onset of disease, we treated these mice with Xudarabine
and monitored changes in the peripheral T cell subsets. As
shown in Fig. 5, we observed an increase in the percentage of
cells with a memory phenotype within the CD4+ and the
CD8+ T cell compartment (memory CD4+: d-3, 42.9 § 13.7;
d3, 70.0 § 14.6,  p < .001; d7, 74.3 § 15.6,  p < .001; d11,
60.2 § 33.9, p = .338; memory CD8+: d-3, 57.6 § 13.2; d3,
87.2 § 5.2,  p = .002; d7, 80.2 § 6.3,  p = .002; d11,
81.5 § 9.9, p < .001) In addition and in line with the results
from our in vitro study of the human model, the absolute
numbers of TH1 cells increased during treatment while TH2
cell numbers declined (Fig. 5c).
Discussion
Chemoimmunotherapy of lymphatic malignancies aims at
the reduction of tumour load on the one hand and establish-
ment of long-lasting tumour control by the patient’s
immune system on the other. Studies in patients with
refractory metastatic melanoma have recently shown that
lymphodepletion, induced by Xudarabine/cyclophospha-
mide treatment, is associated with increased serum levels of
the lymphocyte homeostatic cytokines IL-7 and IL-15, and
that subsequent adoptive cell therapy can mediate signiW-
cant tumour regression [30, 31]. Here, we show that cyto-
toxic treatment with Xudarabine despite its negative impact
on lymphocyte numbers in vitro and in vivo positively
interacts with T cell functions, and that some of these
eVects synergize with cyclophosphamide, a combination
used as backbone of modern CLL treatment.
We observed that CD4+ CD38+ T cells exhibited a
higher sensitivity to in vitro treatment with Xudarabine/
mafosfamide than the CD38¡ T cell counterpart, resulting
in a decrease in percentage of CD38+ CD4+ T cells. CD38
expression on T cells has been shown to reXect chronic
activation and stimulation in various diseases [32, 33] and
also in acute graft rejection [34]. Our own group has
recently shown that the levels of CD38 expression on T
cells predict the course of the disease in male CLL patients
Fig. 4 a Chemonaïve CLL 
patients were treated with Xudar-
abine and cyclophosphamide. 
PBMCs collected before treat-
ment were incubated for 24 h in 
presence (vitro24) or absence of 
1 g/ml Xudarabine. PBMCs 
were also collected on day 1 
(vivo24) and day 3 (vivo72) of 
the FC treatment. All samples 
were co-cultured in vitro for 
6 days with allogeneic DC and 
the T cell proliferation rates on 
day 6 were measured by CFSE 
dilution. Boxplots indicate the 
percentage of proliferating 
CD4+ (white bars) or CD8+ 
(grey bars) T cells (n =6 ) .  
b–d Peripheral blood was col-
lected before treatment (0) and 
after 24 or 72 h of therapy 
(n = 16). Whole blood staining 
was performed of each sample 
and the percentage of (b)C D 3 8 + 
T cells as well as the T cell 
subset distribution of (c)C D 4 + 
and (d)C D 8 + T cells were 
determined by Xow cytometry 
(naïve T cells in normal frames, 
memory T cells in bold frames)Cancer Immunol Immunother (2011) 60:75–85 83
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with higher CD38 expression correlating with a worse clin-
ical prognosis [35], and this was conWrmed by the recent
study by Abousamra et al. [36]. According to these data,
CD38+ T cells, despite their activated phenotype, seem to
fail to perform suYcient tumour control in CLL but rather
support maintenance or even expansion of the malignant
clone. Hence, preferential depletion of CD38+ T cells dur-
ing FC treatment as observed in this study in vitro could
well add to the therapeutic eYcacy of this drug combina-
tion in CLL.
Furthermore, we observed that CD4+ and CD8+ memory
T cells were more resistant than naïve T cells to Xudarabine
and mafosfamide treatment in vitro leading to a decrease in
the naïve/memory T cell ratio. These results are in line with
data from Koike et al. [37] who have shown in a melanoma
mouse model that adoptively transferred naïve T cells dis-
played an activated memory phenotype after lymphodeple-
tion with cyclophosphamide and Xudarabine. Additionally,
in psoriatic arthritis and multiple sclerosis, increased resis-
tance of memory T cells towards Xudarabine or cyclophos-
phamide has been shown [38, 39]. Interestingly, when we
stimulated CLL PBMCs after Xudarabine treatment with
DC or CD3/CD28 beads, we observed an increase in T cell
proliferation as compared to untreated control PBMCs. The
increase in proliferation was mainly found in the memory T
cell subpopulations and was only observed after Xudarabine
treatment, while mafosfamide, although inducing similar
levels of apoptosis, had no eVect on proliferation rates (data
not shown). Since cytotoxic therapy not only reduces the
tumour load but also a signiWcant proportion of immune
cells involved in tumour control, rapid reconstitution of the
T cell compartment after therapy seems crucial in order to
reduce the chance for cancer relapse. Fludarabine, by
enhancing the proliferative capacity especially of memory
T cells, might thereby contribute positively to long-lasting
tumour control.
Gamberale et al. [40] have shown that IFN production
upon PMA/ionomycin stimulation of CD2+ T and NK cells
from CLL patient samples or healthy donor lymphocytes
was signiWcantly increased after 24 h when Xudarabine was
added to the culture. Additionally, they showed that Xudar-
abine did not reduce STAT1 expression, which is activated
in response to IFN, in PBMCs or CD2+ cells from CLL
patients or healthy donors, contrary to what had been
reported before [41]. When we tested T cell functionality
from CLL patients we also found that Xudarabine treatment
enhances the capacity of PBMCs to produce IFN upon
PMA/ionomycin stimulation. Yet, we only observed a sig-
niWcant increase of secreted IFN after a 6 days post-treat-
ment culture. This is probably due to the lower percentage
of T cells (8.4% § 2.4) in our analysed CLL samples when
compared to the samples analysed by Gamberale et al. [40]
(at least 15% CD2+ cells). In extend to that, we could show
that in vitro treatment with Xudarabine, but not mafosfa-
mide enhanced the production of the TH1 cytokine IL-2 as
well, whereas the TH2 cytokine IL-10 was decreased, indi-
cating that in our experimental setting Xudarabine pro-
moted TH1 diVerentiation during T cell activation.
Notably, the observed T cell alterations occurred irre-
spective of the initial CLL/T cell ratio and were also reca-
pitulated in T cells from healthy donors.
In contrast to what we found in our in vitro model, no
changes in the ratios of memory/naïve or regulatory T cells
could be observed in patients in vivo and also the fraction
of CD38+ T cells was stable. Protection from apoptosis pro-
vided by the micro-environment in vivo might be responsi-
ble for this discrepancy. Alternatively, treatment for a
longer period would be necessary to reveal the modulating
eVect of Xudarabine on T cell subsets in vivo.
The results from the tcl1tg mouse model in which we
could follow possible T cell changes for up to 14 days after
in vivo Xudarabine treatment corroborate our results from
the in vitro model and thereby support the time factor
as one possible explanation. Also, when we stimulated
PBMCs from CLL patients treated with Xudarabine and
cyclophosphamide for 3 days with DC, we again observed
Fig. 5 a Peripheral blood from Wve mice was collected 3 days prior to
(d-3), during (d3) and after (d7, d11) Xudarabine treatment (5 days;
35 mg/kg/day). T cells were stained using speciWc antibodies and the
percentage of CD4+ (a)a n d  C D 8 + (b) memory T cells was assessed.
c In a separate experiment, the numbers of peripheral blood TH1 and
TH2 CD4+ T cells prior to (d0) and after Xudarabine treatment (d7, d14)
were determined. One representative result of two experiments is
shown84 Cancer Immunol Immunother (2011) 60:75–85
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a signiWcant increase in T cell proliferation when compared
with non-treated samples. This indicates that FC treatment
lowers the threshold for subsequent T cell expansion by
other means than selective cytodepletion.
In conclusion, our results provide new evidence that
Xudarabine is not only cytotoxic but also able to modulate
distinct functions of the immune system, in particular to
stimulate a shift from naïve to memory T cell subsets, to
lower the threshold for proliferation and to increase TH1
cytokine production. Hence, besides reducing the tumour
load, Xudarabine-induced immune modulation may on the
one hand improve post-treatment tumour control, but on the
other hand also account for the observation that Xudarabine
mono- or combinational therapy increases the incidence of
auto-immune reactions, predominantly autoimmune hae-
molytic anaemia [42, 43].
Acknowledgments We thank Lucia Haginger for the skilful prepa-
ration of CLL patient samples. This work was supported by the Klini-
sche Malignom-und Zytokinforschung Salzburg-Innsbruck GmbH,
grants of the Austrian Science Foundation (SFB021-P11 to R. Greil,
P16153 to I.T., P19481-B12 to A.E., L488-B13 to A.E.), the Austrian
National Bank (13420 to T.N.H., 10990 to A.E.) and the Province of
Salzburg (to R. Greil).
Open Access This article is distributed under the terms of the Cre-
ative Commons Attribution Noncommercial License which permits
any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Finn OJ (2008) Cancer immunology. N Engl J Med 358:2704–
2715
2. Tam CS, Keating MJ (2007) Chemoimmunotherapy of chronic
lymphocytic leukemia. Best Pract Res Clin Haematol 20:479–498
3. Lake RA, Robinson BW (2005) Immunotherapy and chemother-
apy—a practical partnership. Nat Rev Cancer 5:397–405
4. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A,
Kroemer G (2008) The anticancer immune response: indispens-
able for therapeutic success? J Clin Invest 118:1991–2001
5. Baxevanis CN, Perez SA, Papamichail M (2009) Combinatorial
treatments including vaccines, chemotherapy and monoclonal
antibodies for cancer therapy. Cancer Immunol Immunother
58:317–324
6. Dunussi-Joannopoulos K (2002) The combination of chemo-
therapy and systemic immunotherapy and the concept of cure in
murine leukemia and lymphoma. Leuk Lymphoma 43:2075–
2082
7. Frey AB, Monu N (2008) Signaling defects in anti-tumor T cells.
Immunol Rev 222:192–205
8. Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, Greil
R (1998) DiVerential sensitivity of CD4+ and CD8+ T lymphocytes
to the killing eYcacy of Fas (Apo-1/CD95) ligand+ tumor cells in B
chronic lymphocytic leukemia. Blood 91:4273–4281
9. Frydecka I, Kosmaczewska A, Bocko D, Ciszak L, Wolowiec D,
Kuliczkowski K, Kochanowska I (2004) Alterations of the expres-
sion of T-cell-related costimulatory CD28 and downregulatory
CD152 (CTLA-4) molecules in patients with B-cell chronic lym-
phocytic leukaemia. Br J Cancer 90:2042–2048
10. Scrivener S, Goddard RV, Kaminski ER, Prentice AG (2003)
Abnormal T-cell function in B-cell chronic lymphocytic leukae-
mia. Leuk Lymphoma 44:383–389
11. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum
W, Byrd JC, Gribben JG (2008) Chronic lymphocytic leukemia T
cells show impaired immunological synapse formation that can be
reversed with an immunomodulating drug. J Clin Invest
118:2427–2437
12. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E,
Knolle PA, Thomas RK, Bergwelt-Baildon M, Debey S, Hallek
M, Schultze JL (2005) Reduced frequencies and suppressive func-
tion of CD4+CD25hi regulatory T cells in patients with chronic
lymphocytic leukemia after therapy with Xudarabine. Blood
106:2018–2025
13. Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ,
Wierda WG (2005) Increased expression of CD152 (CTLA-4) by
normal T lymphocytes in untreated patients with B-cell chronic
lymphocytic leukemia. Leukemia 19:1788–1793
14. Morrison VA (1998) The infectious complications of chronic lym-
phocytic leukemia. Semin Oncol 25:98–106
15. O’Brien S (1998) Clinical challenges in chronic lymphocytic leu-
kemia. Semin Hematol 35:22–26
16. Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch
HP, Sezer O, Herold M, Knauf W, Wendtner CM, Kuse R, Freund
M, Franke A, Schriever F, Nerl C, Dohner H, Thiel E, Hiddemann
W, Brittinger G, Emmerich B (2001) Fludarabine plus cyclophos-
phamide is an eYcient treatment for advanced chronic lympho-
cytic leukaemia (CLL): results of a phase II study of the German
CLL Study Group. Br J Haematol 114:342–348
17. Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A,
Pasold R, Schlag R, HopWnger G, Hiddemann W, Emmerich B,
Hallek M (2002) Fludarabine combination therapy for the treat-
ment of chronic lymphocytic leukemia. Clin Lymphoma 3:26–35
18. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B,
Villamor N, Colomer D, Cobo F, Perales M, Esteve J, Altes A,
Besalduch J, Ribera JM, Montserrat E (2002) Fludarabine, cyclo-
phosphamide and mitoxantrone in the treatment of resistant or re-
lapsed chronic lymphocytic leukaemia. Br J Haematol 119:976–
984
19. Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F,
AndreeV M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W,
Detry MA, Lynn A, Kantarjian H (2005) Early results of a chemo-
immunotherapy regimen of Xudarabine, cyclophosphamide, and
rituximab as initial therapy for chronic lymphocytic leukemia.
J Clin Oncol 23:4079–4088
20. Tsimberidou AM, Tam C, Abruzzo LV, O’Brien S, Wierda WG,
Lerner S, Kantarjian HM, Keating MJ (2009) Chemoimmunother-
apy may overcome the adverse prognostic signiWcance of 11q
deletion in previously untreated patients with chronic lymphocytic
leukemia. Cancer 115:373–380
21. Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo
L ,  M e i s n e r  D ,  L a m a n  A ,  S u l e c k i  M ,  B u t c h k o  A ,  S c h a e f e r  P ,
Lenzer D, Tarhini A (2009) Chemoimmunotherapy with low-dose
Xudarabine and cyclophosphamide and high dose rituximab in pre-
viously untreated patients with chronic lymphocytic leukemia.
J Clin Oncol 27:498–503
22. Brode S, Cooke A (2008) Immune-potentiating eVects of the
chemotherapeutic drug cyclophosphamide. Crit Rev Immunol
28:109–126
23. Robak T, Korycka A, Kasznicki M, Wrzesien-Kus A, Smolewski
P (2005) Purine nucleoside analogues for the treatment of hemato-
logical malignancies: pharmacology and clinical applications.
Curr Cancer Drug Targets 5:421–444
24. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN,
Pasternack BS (1975) Clinical staging of chronic lymphocytic
leukemia. Blood 46:219–234Cancer Immunol Immunother (2011) 60:75–85 85
123
25. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R,
Russo G, Hardy RR, Croce CM (2002) Human chronic lympho-
cytic leukemia modeled in mouse by targeted TCL1 expression.
Proc Natl Acad Sci USA 99:6955–6960
26. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB,
De Lay MD, Croce CM, Grever MR, Byrd JC (2006) Character-
ization of the TCL-1 transgenic mouse as a preclinical drug devel-
opment tool for human chronic lymphocytic leukemia. Blood
108:1334–1338
27. Holler C, Pinon JD, Denk U, Heyder C, Hofbauer S, Greil R, Egle
A (2009) PKCbeta is essential for the development of chronic lym-
phocytic leukemia in the TCL1 transgenic mouse model: valida-
tion of PKCbeta as a therapeutic target in chronic lymphocytic
leukemia. Blood 113:2791–2794
28. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J
(1999) In vitro evaluation of Xudarabine in combination with
cyclophosphamide and/or mitoxantrone in B-cell chronic lympho-
cytic leukemia. Blood 94:2836–2843
29. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman
MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA,
Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire
BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody
therapy for relapsed indolent lymphoma: half of patients respond
to a four-dose treatment program. J Clin Oncol 16:2825–2833
30. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL,
Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA,
Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM,
Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A,
Rosenberg SA (2005) Adoptive cell transfer therapy following
non-myeloablative but lymphodepleting chemotherapy for the
treatment of patients with refractory metastatic melanoma. J Clin
Oncol 23:2346–2357
31. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula
U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J,
Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J,
Morton K, Laurencot C, White DE, Rosenberg SA (2008) Adop-
tive cell therapy for patients with metastatic melanoma: evaluation
of intensive myeloablative chemoradiation preparative regimens.
J Clin Oncol 26:5233–5239
32. Pavon EJ, Munoz P, Navarro MD, Raya-Alvarez E, Callejas-
Rubio JL, Navarro-Pelayo F, Ortego-Centeno N, Sancho J, Zubiaur
M (2006) Increased association of CD38 with lipid rafts in T cells
from patients with systemic lupus erythematosus and in activated
normal T cells. Mol Immunol 43:1029–1039
33. Savarino A, Bottarel F, Malavasi F, Dianzani U (2000) Role of
CD38 in HIV-1 infection: an epiphenomenon of T-cell activation
or an active player in virus/host interactions? AIDS 14:1079–1089
34. Boleslawski E, BenOthman S, Grabar S, Correia L, Podevin P,
Chouzenoux S, Soubrane O, Calmus Y, Conti F (2008) CD25,
CD28 and CD38 expression in peripheral blood lymphocytes as a
tool to predict acute rejection after liver transplantation. Clin
Transpl 22:494–501
35. Tinhofer I, Rubenzer G, Holler C, Hofstaetter E, Stoecher M, Egle
A, Steurer M, Greil R (2006) Expression levels of CD38 in T cells
predict course of disease in male patients with B-chronic lympho-
cytic leukemia. Blood 108:2950–2956
36. Abousamra NK, El Din MS, Azmy E (2009) T-cell CD38 expres-
sion in B-chronic lymphocytic leukaemia. Hematol Oncol
27:82–89
37. Koike N, Pilon-Thomas S, Mule JJ (2008) Nonmyeloablative che-
motherapy followed by T-cell adoptive transfer and dendritic cell-
based vaccination results in rejection of established melanoma.
J Immunother 31:402–412
38. Gladstone DE, Golightly MG, Brannagan TH III (2007) High dose
cyclophosphamide preferentially targets naive T (CD45/CD4/
RA+) cells in CIDP and MS patients. J Neuroimmunol 190:121–
126
39. Takada K, Danning CL, Kuroiwa T, Schlimgen R, Tassiulas IO,
Davis JC Jr, Yarboro CH, Fleisher TA, Boumpas DT, Illei GG
(2003) Lymphocyte depletion with Xudarabine in patients with
psoriatic arthritis: clinical and immunological eVects. Ann Rheum
Dis 62:1112–1115
40. Gamberale R, Fernandez-Calotti P, Sanchez-Avalos J, Alberto
MF, GeVner J, Giordano M (2006) The eVect of Xudarabine on
interferon-gamma production by lymphoid cells from healthy
donors and patients with B-cell chronic lymphocytic leukemia.
Haematologica 91:574–576
41. Frank DA, Mahajan S, Ritz J (1999) Fludarabine-induced immu-
nosuppression is associated with inhibition of STAT1 signaling.
Nat Med 5:444–447
42. Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T,
Catovsky D (2008) The prognostic signiWcance of a positive direct
antiglobulin test in chronic lymphocytic leukemia: a beneWcial
eVect of the combination of Xudarabine and cyclophosphamide on
the incidence of hemolytic anemia. Blood 111:1820–1826
43. Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R
(2006) Purine antagonists for chronic lymphocytic leukaemia.
Cochrane Database Syst Rev 3:CD004270